|
Oct 9
|
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Oct 8
|
Exact Sciences Schedules Third Quarter 2024 Earnings Call
|
|
Oct 7
|
FDA greenlights Exact Science’s newest home colorectal cancer test
|
|
Oct 7
|
High Growth Tech Stocks in the United States for October 2024
|
|
Oct 7
|
Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test
|
|
Oct 5
|
Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio
|
|
Oct 4
|
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
|
|
Oct 4
|
Exact Sciences Stock Rises After FDA Signs Off On New Cologuard
|
|
Oct 4
|
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
|
|
Oct 4
|
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
|
|
Oct 3
|
How to Find Strong Buy Medical Stocks Using the Zacks Rank
|
|
Sep 6
|
Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?
|
|
Jul 25
|
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 24
|
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Jun 20
|
NGS: the road to personalising cancer care
|
|
Jun 17
|
MGI and SeqOne partner to create end-to-end genomic testing platform
|
|
Jun 13
|
Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns
|
|
Jun 13
|
Is It Time to Buy May's Worst-Performing Nasdaq Stocks?
|
|
Jun 4
|
Illumina names Everett Cunningham as chief commercial officer
|
|
Jun 3
|
Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?
|